Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis Who Participated in the MS-F203 Trial

Next Previous
Trial Profile

Phase 3 Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects With Multiple Sclerosis Who Participated in the MS-F203 Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Acorda Therapeutics

Most Recent Events

  • 20 Sep 2018 Planned number of patients changed from 240 to NULL.
  • 25 Apr 2012 Results presented at the 64th Annual Meeting of the American Academy of Neurology, according to an Acorda Therapeutics media release.
  • 03 Nov 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov record (Extension trial: NCT00648908).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top